Free for academic non-profit institutions. Other users need a Commercial license
The protein encoded by this gene is a member of the MAP kinase family. MAP kinases act as an integration point for multiple biochemical signals, and are involved in a wide variety of cellular processes such as proliferation, differentiation, transcription regulation and development. This kinase is activated by various cell stimuli, and targets specific transcription factors, and thus mediates immediate-early gene expression in response to cell stimuli. The activation of this kinase by tumor-necrosis factor alpha (TNF-alpha) is found to be required for TNF-alpha induced apoptosis. This kinase is also involved in UV radiation induced apoptosis, which is thought to be related to cytochrom c-mediated cell death pathway. Studies of the mouse counterpart of this gene suggested that this kinase play a key role in T cell proliferation, apoptosis and differentiation. Several alternatively spliced transcript variants encoding distinct isoforms have been reported. [provided by RefSeq, Apr 2016]
MAPK8 (Mitogen-Activated Protein Kinase 8) is a Protein Coding gene. Diseases associated with MAPK8 include Fatty Liver Disease and Hepatitis C. Among its related pathways are ATM Pathway and Association Between Physico-Chemical Features and Toxicity Associated Pathways. Gene Ontology (GO) annotations related to this gene include transferase activity, transferring phosphorus-containing groups and protein tyrosine kinase activity. An important paralog of this gene is MAPK10.
JNKs (c-Jun N-terminal kinases) are a group of mitogen-activated protein kinases (MAPKs), originally called stress activated protein kinases (SAPKs), because they are activated by various environmental stresses. They can also be activated by cytokines and growth factors.
GO ID | Qualified GO term | Evidence | PubMed IDs |
---|---|---|---|
GO:0000166 | nucleotide binding | IEA | -- |
GO:0004672 | protein kinase activity | IEA | -- |
GO:0004674 | protein serine/threonine kinase activity | IEA,IDA | 14967141 |
GO:0004705 | JUN kinase activity | TAS | -- |
GO:0004707 | MAP kinase activity | IBA | 21873635 |
GO ID | Qualified GO term | Evidence | PubMed IDs |
---|---|---|---|
GO:0005634 | nucleus | IBA,IDA | 20027304 |
GO:0005654 | nucleoplasm | TAS | -- |
GO:0005737 | cytoplasm | IBA | 21873635 |
GO:0005739 | mitochondrion | IEA | -- |
GO:0005829 | cytosol | TAS | -- |
SuperPathway | Contained pathways | ||
---|---|---|---|
1 | Activated TLR4 signalling | ||
2 | IL-2 Pathway |
ErbB Family Pathway
.59
ErbB4 Pathway
.59
Prolactin Signaling
.54
Growth Hormone Signaling
.49
IL-2 Pathway
.48
|
LPS Stimulated MAPK Signaling
.47
UVC-Induced MAPK Signaling
.44
TREM1 Pathway
.43
HMGB1 Pathway
.36
PI3K Signaling in B-Lymphocyte
.35
|
3 | TNFR1 Pathway |
TNFR1 Pathway
.56
TNF Signaling
.55
Apoptosis and survival TNFR1 signaling pathway
.52
Apoptotic Pathways Triggered By HIV1
.42
|
Apoptosis through Death Receptors
.42
Fas Signaling
.35
|
4 | 4-1BB Pathway |
4-1BB Pathway
.54
CD40 Signaling
.54
CD27 Pathway
.48
NF-KappaB Activation by EBV
.42
|
TNFR2 Pathway
.37
PKR Pathway
.36
SUMO Pathway
.30
|
5 | Development HGF signaling pathway |
Development HGF signaling pathway
.44
Development Neurotrophin family signaling
.44
|
Apoptosis and survival Anti-apoptotic action of membrane-bound ESR1
.35
|
GO ID | Qualified GO term | Evidence | PubMed IDs |
---|---|---|---|
GO:0000165 | MAPK cascade | IEA | -- |
GO:0006468 | protein phosphorylation | IDA,IMP | 22441692 |
GO:0007254 | JNK cascade | IBA,TAS | -- |
GO:0007258 | JUN phosphorylation | IDA | 14967141 |
GO:0009411 | response to UV | IDA | 14967141 |
Name | Status | Disease Links | Group | Role | Mechanism of Action | Clinical Trials |
---|---|---|---|---|---|---|
Minocycline | Approved, Investigational | Pharma | Target, inhibitor | 229 | ||
Tamoxifen | Approved | Pharma | Agonist, Antagonist, Target, modulator | TGF-β modulatory and PKC inhibitory effects, ER antagonist, Anti-Estrogens | 451 | |
Magnesium | Approved, Experimental, Investigational | Pharma | 0 | |||
Anisomycin | Experimental | Pharma | JNK agonist, potent and specific, JNK, SAPK and p38 activator | 0 | ||
2-({2-[(3-HYDROXYPHENYL)AMINO]PYRIMIDIN-4-YL}AMINO)BENZAMIDE | Experimental | Pharma | Target | 0 |
Name | Synonyms | Role | CAS Number | PubChem IDs | PubMed IDs | |
---|---|---|---|---|---|---|
ADP |
|
Agonist, Full agonist, Partial agonist, Gating inhibitor, Antagonist | 58-64-0 |
|
||
c-JUN peptide |
|
610273-01-3 |
|
|
Compound | Action | Cas Number |
---|---|---|
Anisomycin | JNK, SAPK and p38 activator | 22862-76-6 |
CEP 1347 | Inhibitor of JNK signaling | 156177-65-0 |
c-JUN peptide | Peptide inhibitor of JNK/c-Jun interaction | 610273-01-3 |
Compound | Action | Cas Number |
---|---|---|
AEG 3482 | inhibitor of Jun kinase (JNK)-dependent apoptosis | 63735-71-7 |
Anisomycin | JNK agonist, potent and specific | 22862-76-6 |
AS 602801 | Jun Kinase Inhibitor | 848344-36-5 |
AS601245 | c-Jun NH2-terminal protein kinase inhibitor | 345987-15-7 |
BI 78D3 | Competitive JNK inhibitor | 883065-90-5 |
CC-401 | JNK inhibitor,ATP-competitive | 395104-30-0 |
CC-401 hydrochloride | JNK inhibitor | 1438391-30-0 |
CC-930 | JNK inhibitor,potent and selective | 899805-25-5 |
CEP 1347 | JNK inhibitor | 156177-65-0 |
DB07268 | JNK1 inhibitor | 929007-72-7 |
DTP3 | inhibitor of GADD45β/MKK7 complex | |
IQ 3 | 312538-03-7 | |
JIP-1 (153-163) | 438567-88-5 | |
JNK-IN-7 | Selective JNK inhibitor | 1408064-71-0 |
JNK-IN-8 | JNK inhibitor, selective and irreversible | 1410880-22-6 |
PF-03394197(Oclacitinib) | Novel Janus kinase inhibitor | 1208319-26-9 |
Piperine | MAPK inhibitor | 94-62-2 |
SP 600125 | JNK1/2/3 inhibitor | 129-56-6 |
SU 3327 | 40045-50-9 | |
TCS JNK 6o | JNK inhibitor | 894804-07-0 |
ExUns: | 1a | · | 1b | ^ | 2 | ^ | 3 | ^ | 4 | ^ | 5 | ^ | 6 | ^ | 7 | ^ | 8a | · | 8b | ^ | 9a | · | 9b | ^ | 10 | ^ | 11 | ^ | 12a | · | 12b | · | 12c | · | 12d | · | 12e |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
SP1: | - | - | |||||||||||||||||||||||||||||||||||
SP2: | - | - | |||||||||||||||||||||||||||||||||||
SP3: | - | - | |||||||||||||||||||||||||||||||||||
SP4: | - | - | |||||||||||||||||||||||||||||||||||
SP5: | - | - | - | - | |||||||||||||||||||||||||||||||||
SP6: |
This gene was present in the common ancestor of animals and fungi.
Organism | Taxonomy | Gene | Similarity | Type | Details |
---|---|---|---|---|---|
Chimpanzee (Pan troglodytes) |
Mammalia | MAPK8 30 31 |
|
OneToOne | |
Dog (Canis familiaris) |
Mammalia | MAPK8 30 31 |
|
OneToOne | |
Oppossum (Monodelphis domestica) |
Mammalia | mdo-mir-7255 31 |
|
OneToOne | |
Cow (Bos Taurus) |
Mammalia | MAPK8 30 31 |
|
OneToOne | |
Platypus (Ornithorhynchus anatinus) |
Mammalia | -- 31 |
|
OneToMany | |
-- 31 |
|
OneToMany | |||
Mouse (Mus musculus) |
Mammalia | Mapk8 30 17 31 |
|
OneToOne | |
Rat (Rattus norvegicus) |
Mammalia | Mapk8 30 |
|
||
Chicken (Gallus gallus) |
Aves | MAPK8 30 31 |
|
OneToOne | |
Lizard (Anolis carolinensis) |
Reptilia | MAPK8 31 |
|
OneToOne | |
Tropical Clawed Frog (Silurana tropicalis) |
Amphibia | mapk8 30 |
|
||
African clawed frog (Xenopus laevis) |
Amphibia | LOC398499 30 |
|
||
Zebrafish (Danio rerio) |
Actinopterygii | mapk8b 31 |
|
OneToMany | |
mapk8a 30 31 |
|
OneToMany | |||
mapk8 30 |
|
||||
Rainbow Trout (Oncorhynchus mykiss) |
Actinopterygii | Omy.6867 30 |
|
||
African malaria mosquito (Anopheles gambiae) |
Insecta | AgaP_AGAP009461 30 |
|
||
Fruit Fly (Drosophila melanogaster) |
Insecta | bsk 30 31 32 |
|
OneToMany | |
Worm (Caenorhabditis elegans) |
Secernentea | jnk-1 30 31 32 |
|
OneToMany | |
F09C12.2 32 |
|
|
|||
C49C3.10b 32 |
|
|
|||
Y51B9A.9 32 |
|
|
|||
C49C3.10a 32 |
|
|
|||
Baker's yeast (Saccharomyces cerevisiae) |
Saccharomycetes | HOG1 31 |
|
OneToMany | |
Sea Squirt (Ciona savignyi) |
Ascidiacea | -- 31 |
|
OneToMany | |
Sea Vase (Ciona intestinalis) |
Ascidiacea | Cin.8900 30 |
|
SNP ID | Clinical significance and condition | Chr 10 pos | Variation | AA Info | Type |
---|---|---|---|---|---|
725202 | Benign: not provided | 48,409,917(+) | C/T | NON_CODING_TRANSCRIPT_VARIANT,SYNONYMOUS_VARIANT | |
759314 | Likely Benign: not provided | 48,401,765(+) | A/G | NON_CODING_TRANSCRIPT_VARIANT,SYNONYMOUS_VARIANT | |
778386 | Benign: not provided | 48,434,924(+) | G/A | NON_CODING_TRANSCRIPT_VARIANT,SYNONYMOUS_VARIANT,THREE_PRIME_UTR_VARIANT | |
VAR_042258 | A renal clear cell carcinoma sample | p.Gly171Ser | |||
VAR_042259 | A glioblastoma multiforme sample | p.Gly177Arg |
Variant ID | Type | Subtype | PubMed ID |
---|---|---|---|
esv2666099 | CNV | deletion | 23128226 |
esv3623153 | CNV | loss | 21293372 |
esv3623154 | CNV | loss | 21293372 |
nsv1039508 | CNV | gain | 25217958 |
nsv1042677 | CNV | loss | 25217958 |
nsv467190 | CNV | gain | 19166990 |
nsv518744 | CNV | loss | 19592680 |
nsv519701 | CNV | loss | 19592680 |
nsv550811 | CNV | gain | 21841781 |
nsv550812 | CNV | gain | 21841781 |
nsv6587 | CNV | deletion | 18451855 |
nsv825373 | CNV | loss | 20364138 |
Disorder | Aliases | PubMed IDs |
---|---|---|
fatty liver disease |
|
|
hepatitis c |
|
|
hepatitis |
|
|
renal fibrosis |
|
|
non-alcoholic fatty liver disease |
|
|